Should You Buy Shares of CRISPR Therapeutics in February?

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer and various genetic conditions is an obvious home run. CRISPR Therapeutics (NASDAQ: CRSP) won the race to market, partnering with Vertex Pharmaceuticals on Casgevy. After its FDA approval in December 2023, CRISPR Therapeutics remains the only CRISPR company to have received approval for a gene-editing therapy. But CRISPR stock still trades at a fraction of its all-time high, even aft ...